ACRS
Income statement / Annual
Last year (2025), Aclaris Therapeutics Inc's total revenue was $7.83 M,
a decrease of 58.19% from the previous year.
In 2025, Aclaris Therapeutics Inc's net income was -$64.92 M.
See Aclaris Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$7.83 M |
$18.72 M |
$31.25 M |
$29.75 M |
$6.76 M |
$6.48 M |
$4.23 M |
$10.09 M |
$1.68 M |
$0.00 |
| Cost of Revenue |
$2.09 M
|
$2.79 M
|
$18.08 M
|
$11.96 M
|
$4.71 M
|
$5.13 M
|
$4.06 M
|
$6.85 M
|
$1.21 M
|
$120.00 K
|
| Gross Profit |
$5.74 M
|
$15.93 M
|
$13.17 M
|
$17.79 M
|
$2.05 M
|
$1.35 M
|
$172.00 K
|
$3.24 M
|
$476.00 K
|
-$120.00 K
|
| Gross Profit Ratio |
0.73
|
0.85
|
0.42
|
0.6
|
0.3
|
0.21
|
0.04
|
0.32
|
0.28
|
0
|
| Research and Development Expenses |
$52.65 M
|
$33.59 M
|
$98.38 M
|
$77.81 M
|
$43.81 M
|
$29.34 M
|
$64.90 M
|
$63.01 M
|
$39.79 M
|
$33.48 M
|
| General & Administrative Expenses |
$21.97 M
|
$22.20 M
|
$31.10 M
|
$25.13 M
|
$23.62 M
|
$20.53 M
|
$27.16 M
|
$27.65 M
|
$33.11 M
|
$15.09 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$671.00 K
|
$48.00 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$21.97 M
|
$22.20 M
|
$31.10 M
|
$25.13 M
|
$23.62 M
|
$20.53 M
|
$27.83 M
|
$75.65 M
|
$33.11 M
|
$15.09 M
|
| Other Expenses |
$7.49 M
|
$102.07 M
|
-$18.96 M
|
$4.70 M
|
$24.34 M
|
$2.39 M
|
$0.00
|
$0.00
|
$0.00
|
$488.00 K
|
| Operating Expenses |
$82.11 M
|
$157.86 M
|
$110.53 M
|
$107.65 M
|
$91.77 M
|
$52.26 M
|
$92.73 M
|
$138.66 M
|
$72.90 M
|
$48.57 M
|
| Cost And Expenses |
$84.20 M
|
$160.65 M
|
$128.61 M
|
$119.61 M
|
$96.48 M
|
$57.39 M
|
$96.78 M
|
$145.51 M
|
$74.11 M
|
$48.57 M
|
| Interest Income |
$7.64 M
|
$7.95 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$454.00 K
|
$807.00 K
|
$863.00 K
|
$797.00 K
|
$923.00 K
|
$1.32 M
|
$1.59 M
|
$1.32 M
|
$402.00 K
|
$120.00 K
|
| EBITDA |
-$64.47 M |
-$51.72 M |
-$115.45 M |
-$84.36 M |
-$64.46 M |
-$47.20 M |
-$90.23 M |
-$80.78 M |
-$53.45 M |
-$48.57 M |
| EBITDA Ratio |
-8.24
|
-2.76
|
-3.69
|
-2.84
|
-9.53
|
-7.28
|
-21.35
|
-8.01
|
-31.76
|
0
|
| Operating Income Ratio |
-9.76
|
-7.58
|
-3.12
|
-3.02
|
-13.27
|
-7.85
|
-26.27
|
-13.42
|
-43.03
|
0
|
| Total Other Income/Expenses Net |
$11.45 M
|
$9.87 M
|
$8.51 M
|
$2.95 M
|
-$1.14 M
|
-$424.00 K
|
-$2.48 M
|
$2.68 M
|
-$15.99 M
|
$488.00 K
|
| Income Before Tax |
-$64.92 M
|
-$132.07 M
|
-$88.85 M
|
-$86.91 M
|
-$90.87 M
|
-$51.34 M
|
-$113.54 M
|
-$132.74 M
|
-$70.35 M
|
-$48.08 M
|
| Income Before Tax Ratio |
-8.3
|
-7.05
|
-2.84
|
-2.92
|
-13.44
|
-7.92
|
-26.86
|
-13.15
|
-41.8
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$367.00 K
|
$0.00
|
$0.00
|
-$182.00 K
|
$0.00
|
$2.68 M
|
-$1.83 M
|
-$120.00 K
|
| Net Income |
-$64.92 M
|
-$132.07 M
|
-$88.48 M
|
-$86.91 M
|
-$90.87 M
|
-$51.02 M
|
-$161.35 M
|
-$132.74 M
|
-$68.52 M
|
-$48.08 M
|
| Net Income Ratio |
-8.3
|
-7.05
|
-2.83
|
-2.92
|
-13.44
|
-7.87
|
-38.17
|
-13.15
|
-40.71
|
0
|
| EPS |
-0.53 |
-1.71 |
-1.27 |
-1.33 |
-1.6 |
-1.2 |
-3.46 |
-4.03 |
-2.44 |
-2.25 |
| EPS Diluted |
-0.53 |
-1.71 |
-1.27 |
-1.33 |
-1.6 |
-1.2 |
-3.46 |
-4.03 |
-2.44 |
-2.25 |
| Weighted Average Shares Out |
$122.66 M
|
$77.30 M
|
$69.81 M
|
$65.21 M
|
$56.73 M
|
$42.54 M
|
$41.32 M
|
$32.91 M
|
$28.10 M
|
$21.42 M
|
| Weighted Average Shares Out Diluted |
$122.66 M
|
$77.30 M
|
$69.81 M
|
$65.21 M
|
$56.73 M
|
$42.54 M
|
$41.32 M
|
$32.91 M
|
$28.10 M
|
$21.42 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
